Related Experiment Video

Updated: May 20, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway

Saurabh Singh1, Deepak Chitkara, Reza Mehrazin

  • 1Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.

Plos One
|July 7, 2012
PubMed

Insights

Combining paclitaxel (PTX) with Hedgehog (Hh) inhibitor cyclopamine (CYA) effectively reverses chemoresistance in prostate cancer. This combination therapy eliminates cancer stem cell populations and restores tumor suppressor microRNAs, offering new hope for treating resistant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Prostate cancer often relapses due to chemoresistance, rendering standard treatments like paclitaxel (PTX) ineffective.
  • MicroRNAs (miRNAs) and the Hedgehog (Hh) signaling pathway are implicated in the development of chemoresistance and cancer stem cell populations in prostate cancer.

Purpose of the Study:

  • To investigate the roles of miRNAs and the Hh pathway in chemoresistant prostate cancer.
  • To evaluate the efficacy of a combination therapy using paclitaxel (PTX) and the Hh inhibitor cyclopamine (CYA).

Main Methods:

  • Utilized paclitaxel-resistant prostate cancer cell lines (DU145-TXR, PC3-TXR) and clinical prostate tissues.
  • Assessed drug sensitivity, apoptosis, and cancer stem cell-like side populations (SP) using Hoechst 33342 flow cytometry.
  • Performed microRNA profiling and analyzed gene expression, including P-glycoprotein (P-gp) efflux protein.

Main Results:

  • Combination therapy with PTX and CYA significantly enhanced cytotoxicity and reduced SP cell numbers compared to monotherapy.
  • SP cells, enriched in G0/G1 phase and expressing higher stem cell markers, were effectively eliminated by the combination treatment.
  • The combination therapy restored the expression of tumor suppressor miRNAs (miR34a, miR200c) and decreased P-gp expression.

Conclusions:

  • Supplementing paclitaxel with the Hh inhibitor cyclopamine can reverse paclitaxel chemoresistance in androgen-independent, metastatic prostate cancer.
  • The combination therapy effectively eliminates cancer stem cell-like side populations and modulates key molecular pathways involved in chemoresistance.
  • This therapeutic strategy holds promise for overcoming treatment resistance in advanced prostate cancer.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis07:26

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis

Published on: January 31, 2025

Related Concept Videos

Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...